Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of hepatocellular carcinoma with antiviral therapy.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2018
Same author

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2018
Same author

Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.

Alimentary pharmacology & therapeutics·2017
Same author

Determination of hepatitis B phenotype using biochemical and serological markers.

Journal of viral hepatitis·2016
Same author

Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Alimentary pharmacology & therapeutics·2016
Same journal

The Role of Telemedicine on Interhospital Transfer Outcomes : A Systematic Review.

Annals of internal medicine·2026
Same journal

Prolonged Short Sleep and Its Effect on Body Weight and Composition : A Pooled Analysis of Randomized Trials.

Annals of internal medicine·2026
Same journal

In AF, LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 y.

Annals of internal medicine·2026
Same journal

How AI is affecting medical journals.

Annals of internal medicine·2026
Same journal

In adults with COPD, the BLISS score predicted risk for acute respiratory hospital admission at 2 y.

Annals of internal medicine·2026
Same journal

In AF at risk for stroke and bleeding, LAAC was not noninferior to medical therapy for a composite of thromboembolic and safety events.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C.

M Shindo1, A M Di Bisceglie, L Cheung

  • 1National Institutes of Health, Bethesda, Maryland.

Annals of Internal Medicine
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Alpha-interferon therapy for chronic hepatitis C reduced hepatitis C viral (HCV) RNA in serum. Most patients responding to treatment achieved undetectable HCV RNA levels, indicating therapy effectiveness.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Experiment Videos

Last Updated: Jun 23, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis C is a significant global health concern.
  • Hepatitis C virus (HCV) infection can lead to long-term liver damage.
  • Effective antiviral therapies are crucial for managing chronic hepatitis C.

Purpose of the Study:

  • To evaluate the impact of alpha-interferon therapy on serum hepatitis C viral RNA levels.
  • To correlate viral RNA reduction with clinical and biochemical responses in chronic hepatitis C patients.

Main Methods:

  • Retrospective analysis of serum samples from a randomized, double-blind, placebo-controlled trial.
  • Testing for hepatitis C virus (HCV) RNA and anti-HCV antibodies using polymerase chain reaction and ELISA.
  • Quantification of viral RNA and antibody titers by serial end-point dilution.

Main Results:

  • HCV RNA was detected in 95% of patients at baseline.
  • Alpha-interferon responders showed significant decreases in serum HCV RNA, with 81% achieving undetectable levels.
  • Non-responders and placebo groups largely maintained detectable HCV RNA.

Conclusions:

  • Clinical and biochemical improvements in chronic hepatitis C correlate with the loss of detectable HCV RNA.
  • Alpha-interferon therapy is associated with viral clearance in a significant proportion of responders.
  • Monitoring HCV RNA is a valuable indicator of treatment efficacy.